Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - rivaroxaban
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp9783bb619d590edd01b19075a96dfce9
identifier: http://ema.europa.eu/identifier
/EU/1/21/1588/001 Blister (PVC/PVdC/alu) 10 tablets
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Rivaroxaban Viatris 2.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-9783bb619d590edd01b19075a96dfce9
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1588/001 Blister (PVC/PVdC/alu) 10 tablets
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - rivaroxaban
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
You have been given Rivaroxaban Viatris because
or
Rivaroxaban Viatris contains the active substance rivaroxaban and belongs to a group of medicines called antithrombotic agents. It works by blocking a blood clotting factor (factor Xa) and thus reducing the tendency of the blood to form clots.
Do not take Rivaroxaban Viatris
if you have a liver disease which leads to an increased risk of bleeding
Do not take Rivaroxaban Viatris and tell your doctor if any of these apply to you.
Warnings and precautions
Talk to your doctor or pharmacist before taking Rivaroxaban Viatris.
Rivaroxaban Viatris should not be used in combination with certain other medicines which reduce blood clotting such as prasugrel or ticagrelor other than acetylsalicylic acid and clopidogrel/ticlopidine.
Take special care with Rivaroxaban Viatris
If any of the above apply to you, tell your doctor before you take Rivaroxaban Viatris. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation.
If you need to have an operation
Children and adolescents Rivaroxaban Viatris 2.5 mg tablets are not recommended for people under 18 years of age. There is not enough information on their use in children and adolescents.
Other medicines and Rivaroxaban Viatris Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including medicines obtained without a prescription.
If any of the above apply to you, tell your doctor before taking Rivaroxaban Viatris, because the effect of Rivaroxaban Viatris may be increased. Your doctor will decide, if you should be treated with this medicine and if you should be kept under closer observation. If your doctor thinks that you are at increased risk of developing stomach or bowel ulcers, he may also use a preventative ulcer treatment.
If any of the above apply to you, tell your doctor before taking Rivaroxaban Viatris, because the effect of Rivaroxaban Viatris may be reduced. Your doctor will decide, if you should be treated with Rivaroxaban Viatris and if you should be kept under closer observation.
Pregnancy and breast-feeding Do not take Rivaroxaban Viatris if you are pregnant or breast-feeding. If there is a chance that you could become pregnant, use a reliable contraceptive while you are taking Rivaroxaban Viatris. If you become pregnant while you are taking this medicine, tell your doctor immediately, who will decide how you should be treated.
Driving and using machines
Rivaroxaban Viatris may cause dizziness (common side effect) or fainting (uncommon side effect) (see section 4, Possible side effects ). You should not drive, ride a bicycle or use any tools or machines if you are affected by these symptoms.
Rivaroxaban Viatris contains lactose and sodium If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
How much to take
The recommended dose is one 2.5 mg tablet twice a day. Take Rivaroxaban Viatris around the same time every day (for example, one tablet in the morning and one in the evening). This medicine can be taken with or without food.
If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take Rivaroxaban Viatris. The tablet may be crushed and mixed with water or apple puree immediately before you take it.
If necessary, your doctor may also give you the crushed Rivaroxaban Viatris tablet through a stomach tube.
Rivaroxaban Viatris will not be given to you on its own.
Your doctor will also tell you to take acetylsalicylic acid. If you get Rivaroxaban Viatris after an acute coronary syndrome, your doctor may tell you to also take clopidogrel or ticlopidine.
If you get Rivaroxaban Viatris after a procedure to open a narrowed or closed artery of your leg to restore blood flow, your doctor may also prescribe clopidogrel for you to take in addition to acetylsalicylic acid for a short while.
Your doctor will tell you how much of these to take (usually between 75 to 100 mg acetylsalicylic acid daily or a daily dose of 75 to 100 mg acetylsalicylic acid plus a daily dose of either 75 mg clopidogrel or a standard daily dose of ticlopidine).
When to start Rivaroxaban Viatris Treatment with Rivaroxaban Viatris after an acute coronary syndrome should be started as soon as possible after stabilisation of the acute coronary syndrome, at the earliest 24 hours after admission to hospital and at the time when parenteral (via injection) anticoagulation therapy would normally be stopped.
Your doctor will tell you when to start treatment with Rivaroxaban Viatris if you have been diagnosed with coronary artery disease or peripheral artery disease.
Your doctor will decide how long you must continue treatment.
If you take more Rivaroxaban Viatris than you should Contact your doctor immediately if you have taken too many Rivaroxaban Viatris tablets. Taking too much Rivaroxaban Viatris increases the risk of bleeding.
If you forget to take Rivaroxaban Viatris Do not take a double dose to make up for a missed dose. If you miss a dose, take your next dose at the usual time.
If you stop taking Rivaroxaban Viatris Take Rivaroxaban Viatris on a regular basis and for as long as your doctor keeps prescribing it.
Do not stop taking Rivaroxaban Viatris without talking to your doctor first. If you stop taking this medicine, it may increase your risk of having another heart attack or stroke or dying from a disease related to your heart or your blood vessels.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Rivaroxaban Viatris can cause side effects, although not everybody gets them.
Like other similar medicines to reduce the formation of blood clots, Rivaroxaban Viatris may cause bleeding which may potentially be life threatening. Excessive bleeding may lead to a sudden drop in blood pressure (shock). In some cases the bleeding may not be obvious.
Tell your doctor immediately if you experience any of the following side effects:
Signs of bleeding
Signs of severe skin reactions
Signs of severe allergic reactions
bleeding into the eye (including bleeding from the whites of the eyes)
rash, itchy skin
blood tests may show an increase in some liver enzymes
thrombocytopenia (low number of platelets, which are cells that help blood to clot)
hives
collection of blood (haematoma) in the groin as a complication of the cardiac procedure where a catheter is inserted in your leg artery (pseudoaneurysm)
Very rare (may affect up to 1 in 10,000 people)
increased pressure within muscles of the legs or arms after a bleeding, which leads to pain, swelling, altered sensation, numbness or paralysis (compartment syndrome after a bleeding)
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and on each blister or bottle after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Crushed tablets Crushed tablets are stable in water or apple puree for up to 2 hours.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Rivaroxaban Viatris contains
What Rivaroxaban Viatris looks like and contents of the pack Rivaroxaban Viatris 2.5 mg film-coated tablets are light yellow to yellow coloured, round, biconvex, bevelled edge tablets (diameter 5.4 mm) and marked with RX on side and 1 on the other side.
They come in
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Viatris Limited Damastown Industrial Park Mulhuddart Dublin DUBLIN Ireland
Manufacturer
Mylan Germany GmbH Benzstrasse 1 Bad Homburg, Hesse, 61352, Germany
Mylan Hungary Kft Mylan utca 1,
Kom rom,
H-2900,
Hungary
McDermott Laboratories Limited t/a Gerard Laboratories 35/36 Baldoyle Industrial Estate,
Grange Road,
Dublin 13,
Ireland
Medis International (Bolatice), Prumyslova 961/16,
Bolatice,
74723,
Czechia
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien ViatrisT l/Tel: + 32 (0)2 658 61 Lietuva Mylan Healthcare UAB
Tel: +370 5 205 1
: +359 2 44 55 Luxembourg/Luxemburg ViatrisT l/Tel: + 32 (0)2 658 61 (Belgique/Belgien)
esk republika Viatris CZ .s.r.o. Tel: + 420 222 004 Magyarorsz g Viatris HealthcareKft Tel: + 36 1 465 2Danmark Viatris ApS Tel: +45 28 11 69 Malta V.J. Salomone Pharma Ltd Tel: + 356 21 22 01 Deutschland Viatris Healthcare GmbH Tel: +49 800 0700 Nederland Mylan BV Tel: +31 (0)20 426 3Eesti BGP Products Switzerland GmbH Eesti filiaal
Tel: + 372 6363 Norge Viatris AS Tel: + 47 66 75 33
Viatris Hellas Ltd : +30 210 0 100 sterreich Arcana Arzneimittel GmbH Tel: +43 1 416 2Espa a Viatris Pharmaceuticals, S.L.U. Tel: + 34 900 102 Polska Mylan Healthcare Sp. z. o.o. Tel: + 48 22 546 64 France Viatris Sant
T el: +33 4 37 25 75 Portugal Mylan, Lda. Tel: + 351 21 412 72 Hrvatska Viatris Hrvatska d.o.o. Tel: +385 1 23 50 Rom nia BGP Products SRL Tel: +40 372 579 Ireland Mylan Ireland Limited Tel: +353 (0) 87 11Slovenija Viatris d.o.o . Tel: + 386 1 23 63 sland Slovensk republika
Icepharma hf S m i: +354 540 8Viatris Slovakia s.r.o. Tel: +421 2 32 199 Italia Viatris Italia S.r.l. Tel: + 39 02 612 46Suomi/Finland Viatris Oy Puh/Tel: +358 20 720 9
Varnavas Hadjipanayis Ltd. : +357 2220 7Sverige Viatris AB
Tel: + 46 8 630 19 Latvija Mylan Healthcare SIA Tel: +371 676 055 United Kingdom (Northern Ireland) Mylan IRE Healthcare Limited Tel: +353 18711This leaflet was last revised in {MM/YYYY}.
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-9783bb619d590edd01b19075a96dfce9
Resource Composition:
Generated Narrative: Composition composition-en-9783bb619d590edd01b19075a96dfce9
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1588/001 Blister (PVC/PVdC/alu) 10 tabletsstatus: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - rivaroxaban
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp9783bb619d590edd01b19075a96dfce9
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp9783bb619d590edd01b19075a96dfce9
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1588/001 Blister (PVC/PVdC/alu) 10 tabletstype: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Rivaroxaban Viatris 2.5 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en